| Anti-Cancer Drug | Use of the Anti-Cancer Drug (N) | Presence of Mucosal Pathology (%) | p-value | Presence of Oral Mucositis (%) | p-value |
|---|---|---|---|---|---|
| Antimetabolites | Yes (20) No (21) |
9 (45%) 6 (29%) |
0.341 | 6 (30%) 4 (19%) |
0.484 |
| Cytotoxic antibiotics | Yes (13) No (28) |
10 (77%) 5 (18%) |
<0.001 | 7 (54%) 3 (11%) |
0.005 |
| Alkylating agent | Yes (10) No (31) |
6 (60%) 9 (29%) |
0.013 | 5 (50%) 5 (16%) |
0.045 |
| Plant alkaloids | Yes (9) No (32) |
4 (44%) 11 (34%) |
0.701 | 3 (33%) 7 (22%) |
0.662 |
| Topoisomerases inhibitor |
Yes (13) No (28) |
7 (54%) 8 (29%) |
0.168 | 4 (31%) 6 (21%) |
0.698 |
| RTK inhibitor | Yes (5) No (36) |
2 (40%) 13 (36%) |
1.000 | 1 (20%) 9 (25%) |
1.000 |